uniQure (NASDAQ:QURE) Shares Up 8.3% – Here’s What Happened

uniQure N.V. (NASDAQ:QURE)’s stock price was up 8.3% during mid-day trading on Tuesday . The company traded as high as $48.66 and last traded at $48.09. 456,705 shares were traded during trading, a decline of 83% from the average session volume of 2,715,994 shares. The stock had previously closed at $44.39.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
• Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
• Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
• Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title

Analysts Set New Price Targets

A number of research analysts recently weighed in on QURE shares. The Goldman Sachs Group boosted their target price on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Royal Bank Of Canada lifted their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Chardan Capital upped their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $58.92.

uniQure Stock Down 0.4%

The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -14.04 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The stock has a fifty day moving average of $26.59 and a two-hundred day moving average of $22.65.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. Sell-side analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current year.

Insider Buying and Selling at uniQure

In other news, Director Jack Kaye sold 5,295 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $42.57, for a total value of $225,408.15. Following the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,106,649.72. This represents a 16.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeannette Potts sold 5,237 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $27.67, for a total transaction of $144,907.79. Following the sale, the insider owned 133,246 shares of the company’s stock, valued at approximately $3,686,916.82. This trade represents a 3.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 324,134 shares of company stock worth $12,778,769. Company insiders own 4.65% of the company’s stock.

Institutional Trading of uniQure

Large investors have recently bought and sold shares of the business. State Street Corp boosted its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after purchasing an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after acquiring an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC bought a new position in uniQure during the fourth quarter worth $33,062,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.